卡非佐米/Carfilzomib，是一种选择性蛋白酶体抑制剂

Trade names Kyprolis

Other names PX-171-007

CAS Number 868540-17-4

Formula C40H57N5O7

Molar mass 719.924 g·mol−1

卡非佐米/Carfilzomib，是一种选择性蛋白酶体抑制剂。在化学上，它是一种四肽环氧酮（tetrapeptide epoxyketone）和环氧霉素（epoxomicin）的类似物。此成分是由Onyx Pharmaceuticals研发而出的。

Carfilzomib covalently irreversibly binds to and inhibits the chymotrypsin-like activity of the 20S proteasome, an enzyme that degrades unwanted cellular proteins. Carfilzomib displays minimal interactions with non-proteasomal targets, thereby improving safety profiles over bortezomib. Inhibition of proteasome-mediated proteolysis results in a build-up of polyubiquitinated proteins, which may cause cell cycle arrest, apoptosis, and inhibition of tumor growth.